Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy
Glioblastoma (GBM) is an aggressive and lethal malignancy of the central nervous system with a median survival rate of 15 months. We investigated the combined anticancer effects of nerve growth factor (NGF), cathelicidin (LL-37), and protegrin-1 (PG-1) with chemotherapy (temozolomide, doxorubicin, c...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2023-11-01
|
| Col·lecció: | Biomedicines |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2227-9059/11/11/3009 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|